Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy

Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy

To examine the efficacy of dose escalating radiotherapy into patients with cT3b or T4 localized prostate cancer, we compared Group A (86 conventional dose external beam radiotherapy: EBRT group, treated with 70–72 Gy) and group B (39 high dose EBRT group (HDEBRT group, 74–80 Gy) and 124 high-dose-ra...

Full description

Bibliographic Details
Main Authors: Hideya Yamazaki, Gen Suzuki, Koji Masui, Norihiro Aibe, Daisuke Shimizu, Takuya Kimoto, Ken Yoshida, Satoaki Nakamura, Haruumi Okabe
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
prostate cancer
T3b–T4
very high risk
high dose rate
brachytherapy
IMRT
Online Access:https://www.mdpi.com/2072-6694/13/8/1856

Internet

https://www.mdpi.com/2072-6694/13/8/1856

Similar Items